Clinical Trial: NCT03081689
Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Spanish Lung Cancer Group |
| Information Provided By: | Spanish Lung Cancer Group |
| Last Update Posted: | 2024-12-04 |
Study Overview
Brief Summary
Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months.
Official Title
Conditions
Intervention / Treatment
- Drug: Nivolumab 360 mg
- Drug: Paclitaxel 200mg/m2
- Drug: Carboplatin AUC 6
Other Study ID Numbers
- GECP 16/03_NADIM
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Spanish Lung Cancer Group |
| Information Provided By: | Spanish Lung Cancer Group |
| Last Update Posted: | 2024-12-04 |
Study Overview
Brief Summary
Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months.
Official Title
Conditions
Intervention / Treatment
- Drug: Nivolumab 360 mg
- Drug: Paclitaxel 200mg/m2
- Drug: Carboplatin AUC 6
Other Study ID Numbers
- GECP 16/03_NADIM